Browse Tag

FDA

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

Updated: Sunday, December 14, 2025 (markets closed; prices reflect the most recent close). GSK plc (LSE: GSK / NYSE: GSK) heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion
Stryker (SYK) Stock This Week: Dividend Hike, New COO, FDA Recall Watchlist — Outlook for the Week Ahead (Updated Dec. 12, 2025)

Stryker (SYK) Stock This Week: Dividend Hike, New COO, FDA Recall Watchlist — Outlook for the Week Ahead (Updated Dec. 12, 2025)

Stryker Corporation (NYSE: SYK) closed Friday, December 12, 2025, at $354.09, finishing the session up 0.32% and stabilizing after a choppy stretch that began with a sharp selloff early in the week. Investing.com+1 Stryker is a global medical technology company
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

(SEO): Pfizer stock (NYSE: PFE) held firm after the bell on Dec. 12, 2025. Here’s the full roundup of today’s headlines, analyst targets, and what to watch before the next market session. Pfizer, Inc. (NYSE: PFE) wrapped up Friday’s session
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer Inc. (NYSE: PFE) ended the Friday, December 12, 2025 session slightly higher—and moved only modestly in after-hours trading—after a busy day of headline-driven catalysts. Investors weighed a newly declared $0.43 quarterly dividend, fresh FDA-related reporting tied to COVID-19 vaccine
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY)
12 December 2025
1 2 3
Go toTop